Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13

Blood

Volumn 107, Issue 3, 2006, Pages 955-964

  Bonnefoy, Arnaud ^b   Daenens, Kim ^b   Feys, Hendrik B ^b   De Vos, Rita ^b   Vandervoort, Petra ^b   Vermylen, Jos ^b   Lawler, Jack ^b   Hoylaerts, Marc F ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; CELL ADHESION; CONTROLLED STUDY; ENDOTHELIUM; HEMOSTASIS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; THROMBOCYTE; THROMBOTIC THROMBOCYTOPENIC PURPURA; THROMBUS; WILD TYPE;

EID: 31544475409     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2004-12-4856     Document Type: Article

References (47)

1. Ruggeri ZM. Mechanisms initiating platelet thrombus formation. Thromb Haemost. 1997;78:611-616.
2. Ware J, Ruggeri ZM. Platelet adhesion receptors and their participation in hemostasis and thrombosis. Drugs Today (Barc). 2001;37:265-274.
3. Ni H, Denis CV, Subbarao S, et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest. 2000;106:385-392.
4. Ni H, Yuen PS, Papalia JM, et al. Plasma fibronectin promotes thrombus growth and stability in injured arterioles. Proc Natl Acad Sci U S A. 2003;100:2415-2419.
5. Tuszynski GP, Nicosia RF. The role of thrombospondin-1 in tumor progression and angiogenesis. Bioessays. 1996;18:71-76.
6. Dubernard V, Arbeille BB, Lemesle MB, Legrand C. Evidence for an alpha-granular pool of the cytoskeletal protein alpha-actinin in human platelets that redistributes with the adhesive glycoprotein thrombospondin-1 during the exocytotic process. Arterioscler Thromb Vasc Biol. 1997;17:2293-2305.
7. Lawler J, Duquette M, Urry L, McHenry K, Smith TF. The evolution of the thrombospondin gene family. J Mol Evol. 1993;36:509-516.
8. Legrand C, Thibert V, Dubernard V, Begault B, Lawler J. Molecular requirements for the interaction of thrombospondin with thrombin-activated human platelets: modulation of platelet aggregation. Blood. 1992;79:1995-2003.
9. Legrand C, Morandi V, Mendelovitz S, Shaked H, Hartman JR, Panet A. Selective inhibition of platelet macroaggregate formation by a recombinant heparin-binding domain of human thrombospondin. Arterioscler Thromb. 1994;14:1784-1791.
10. Bonnefoy A, Hantgan R, Legrand C, Frojmovic MM. A model of platelet aggregation involving multiple interactions of thrombospondin-1, fibrinogen, and GPIIbIIIa receptor. J Biol Chem. 2001;276:5605-5612.
11. Chung J, Gao AG, Frazier WA. Thrombspondin acts via integrin-associated protein to activate the platelet integrin alphaIIbbeta3. J Biol Chem. 1997;272:14740-14746.
12. Chung J, Wang XQ, Lindberg FP, Frazier WA. Thrombospondin-1 acts via IAP/CD47 to synergize with collagen in alpha2beta1-mediated platelet activation. Blood. 1999;94:642-648.
13. Frazier WA, Gao AG, Dimitry J, et al. The thrombospondin receptor integrin-associated protein (CD47) functionally couples to heterotrimeric Gi. J Biol Chem. 1999;274:8554-8560.
14. Jurk K, Clemetson KJ, de Groot PG, et al. Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor. FASEB J. 2003;17:1490-1492.
15. Lagadec P, Dejoux O, Ticchioni M, et al. Involvement of a CD47-dependent pathway in platelet adhesion on inflamed vascular endothelium under flow. Blood. 2003;101:4836-4843.
16. Lawler J, Sunday M, Thibert V, et al. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest. 1998;101:982-992.
17. Topol EJ, McCarthy J, Gabriel S, et al. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation. 2001;104:2641-2644.
18. Zhao XM, Hu Y, Miller GG, Mitchell RN, Libby P. Association of thrombospondin-1 and cardiac allograft vasculopathy in human cardiac allografts. Circulation. 2001;103:525-531.
19. Pimanda JE, Ganderton T, Maekawa A, et al. Role of thrombospondin-1 in control of von Willebrand factor multimer size in mice. J Biol Chem. 2004;279:21439-21448.
20. Dubernard V, Legrand C. Characterization of the binding of thrombospondin to human platelets and its association with the platelet cytoskeleton. J Lab Clin Med. 1991;118:446-457.
21. Veyradier A, Girma JP. Assays of ADAMTS-13 activity. Semin Hematol. 2004;41:41-47.
22. Theilmeier G, Lenaerts T, Remacle C, Collen D, Vermylen J, Hoylaerts MF. Circulating activated platelets assist THP-1 monocytoid/endothelial cell interaction under shear stress. Blood. 1999;94:2725-2734.
23. Theilmeier G, Michiels C, Spaepen E, et al. Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood. 2002;99:4486-4493.
24. Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemost. 1987;58:1078-1084.
25. Oury C, Kuijpers MJ, Toth-Zsamboki E, et al. Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype. Blood. 2003;101:3969-3976.
26. André P, Denis CV, Ware J, et al. Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood. 2000;96:3322-3328.
27. Vanschoonbeek K, Feijge MA, Van Kampen RJ, et al. Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics. J Thromb Haemost. 2004;2:476-484.
28. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002;100:4033-4039.
29. Dong JF, Moake JL, Bernardo A, et al. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem. 2003;278:29633-29639.
30. Mast AE, Stadanlick JE, Lockett JM, Dietzen DJ, Hasty KA, Hall CL. Tissue factor pathway inhibitor binds to platelet thrombospondin-1. J Biol Chem. 2000;275:31715-31721.
31. McGregor JL, Catimel B, Parmentier S, Clezardin P, Dechavanne M, Leung LL. Rapid purification and partial characterization of human platelet glycoprotein IIIb: interaction with thrombospondin and its role in platelet aggregation. J Biol Chem. 1989;264:501-506.
32. Lawler J, Weinstein R, Hynes RO. Cell attachment to thrombospondin: the role of ARG-GLYASP, calcium, and integrin receptors. J Cell Biol. 1988;107:2351-2361.
33. Lawler J, Hynes RO. An integrin receptor on normal and thrombasthenic platelets that binds thrombospondin. Blood. 1989;74:2022-2027.
34. Gao AG, Lindberg FP, Finn MB, Blystone SD, Brown EJ, Frazier WA. Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. J Biol Chem. 1996;271:21-24.
35. Hogg PJ. Thrombospondin 1 as an enzyme inhibitor. Thromb Haemost. 1994;72:787-792.
36. Boukerche H, McGregor JL. Characterization of an anti-thrombospondin monoclonal antibody (P8) that inhibits human blood platelet functions: normal binding of P8 to thrombin-activated Glanzmann thrombasthenic platelets. Eur J Biochem. 1988;171:383-392.
37. Dixit VM, Haverstick DM, O'Rourke KM, et al. A monoclonal antibody against human thrombospondin inhibits platelet aggregation. Proc Natl Acad Sci U S A. 1985;82:3472-3476.
38. Dixit VM, Haverstick DM, O'Rourke KM, et al. Effects of anti-thrombospondin monoclonal antibodies on the agglutination of erythrocytes and fixed, activated platelets by purified thrombospondin. Biochemistry. 1985;24:4270-4275.
39. Vailhe B, Feige JJ. Thrombospondins as anti-angiogenic therapeutic agents. Curr Pharm Des. 2003;9:583-588.
40. Calzada MJ, Zhou L, Sipes JM, et al. α4β1 integrin mediates selective endothelial cell responses to thrombospondins 1 and 2 in vitro and modulates angiogenesis in vivo. Circ Res. 2004;94:462-470.
41. Rybak ME. Glycoproteins IIb and IIIa and platelet thrombospondin in a liposome model of platelet aggregation. Thromb Haemost. 1986;55:240-245.
42. Leung LL. Role of thrombospondin in platelet aggregation. J Clin Invest. 1984;74:1764-1772.
43. Padilla A, Moake JL, Bernardo A, et al. P-selectin anchors newly released ultra-large von Willebrand factor multimers to the endothelial cell surface. Blood. 2003;103:2150-2156.
44. Lopez JA, Dong JF. Cleavage of von Willebrand factor by ADAMTS-13 on endothelial cells. Semin Hematol. 2004;41:15-23.
45. Lammle B, Kremer Hovinga JA, Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost. 2005;3:1663-1675.
46. Paleolog EM, Crossman DC, McVey JH, Pearson JD. Differential regulation by cytokines of constitutive and stimulated secretion of von Willebrand factor from endothelial cells. Blood. 1990;75:688-695.
47. Dong JF. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost. 2005;3:1710-1716.